Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 7879691, 6 pages
Research Article

Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol

Department of Ophthalmology and Visual Science, Chiba University, Graduate School of Medicine, Chiba, Japan

Correspondence should be addressed to Toshiyuki Oshitari; moc.loa@iirat

Received 13 July 2017; Accepted 12 November 2017; Published 4 December 2017

Academic Editor: Atsushi Mizota

Copyright © 2017 Tomomi Kaiho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The purpose of this study was to determine the efficacy of one-year treatment of diabetic macular edema (DME) with intravitreal aflibercept (IVA) injections on a practical protocol. The medical records of 51 eyes of 43 patients who were diagnosed with DME and had received IVA treatments were reviewed. The best-corrected visual acuity (BCVA) and the central macular thickness (CMT) were measured at the baseline and at 1, 3, 6, and 12 months after the IVA. The mean number of IVA injections was . The mean BCVA was significantly better and the CMT was thinner after the IVA at all follow-up times (). The BCVA was better in eyes with a serous retinal detachment (SRD) than without a SRD (). There was a significant correlation between the photoreceptor outer segment (PROS) length and BCVA at the baseline and at 12 months after the IVA (). A fewer number of IVA injections significantly improved the BCVA and the CMT in eyes with DME after one-year treatment. IVA was more effective in the SRD+ group than in the SRD− group. The PROS length may be a predictive marker for visual outcomes after one-year treatment with IVA for DME (IRB#2272).